🟢 Outlook Therapeutics is trading 8.2% up today extending rally after FDA approval for LYTENAVA

Outlook Therapeutics is trading 8.2% up at $1.52 in pre-market, extending last week’s rally following a significant regulatory milestone.

• The move follows the July 24 FDA approval for LYTENAVA™ (bevacizumab-vikg), the first ophthalmic bevacizumab specifically approved for wet AMD treatment.
• Shares are seeing renewed investor interest amid a broadly risk-on market environment, with index futures trading higher on improved macro sentiment.